HSCs (hHSCs) are characterized by a significantly higher baseline intracellular pH (pHi) in comparison to nonactivated, freshly isolated HSCs, due to an increased proton (H 1 ) extrusion rate. (3, 4) The possibility of modulating the profibrogenic phenotype of HSCs by acting on the machinery responsible for the increased pHi has been repeatedly suggested but not confirmed. One of the most recently characterized systems involved in the maintenance of pHi is vacuolar adenosine triphosphatase (v-ATPase). This heteromultimeric enzyme complex is composed of at least 14 different independent subunits assembled to a cytosolic adenosine triphosphate (ATP) hydrolytic domain (V 1 ) and a membrane-bound proton-translocating domain (V 0 ) docked on/in the membrane. v-ATPase is located both in endomembrane systems and in the plasma membrane and is therefore able to maintain pHi by actively transporting protons from the cytoplasm to the lumen of intracellular compartments, i.e., lysosomes, as well as from the cytoplasm to the plasma membrane, i.e., into the extracellular space. (5) Recent experimental evidence in the kidney suggests that v-ATPase is regulated by the energy-sensing enzyme adenosine monophosphate-activated protein kinase (AMPK). (6, 7) AMPK is a heterotrimeric serine/threonine kinase consisting of three subunits, a, b, and c, each expressed in different isoforms as the result of distinct gene codifications. The AMPK a1 subunit (AMPKa1) is widely expressed across tissues and is predominantly localized in the cytosol, whereas AMPKa2 is more restricted in its tissue and intracellular distribution. (8, 9) Both AMPKa isoforms are expressed in human liver tissue. (10) Studies have shown that AMPK activation is characterized by phosphorylation of the threonine residue (Thr172) in the activation loop of AMPKa1 and AMPKa2. Once activated, AMPK stimulates ATP-generating catabolic pathways and inhibits energy-consuming processes. (9) Activation of AMPK has also been shown to interfere with the profibrogenic HSC phenotype by inhibiting platelet-derived growth factor BB (PDGF-BB)-induced cell proliferation and transforming growth factor-beta (TGF-b)-induced fibrogenic responses, (11) (12) (13) suggesting that agents that promote AMPK activation could be employed as antifibrotic agents.
Until now, no information has been available regarding the expression and distribution of v-ATPase in hHSCs and, more precisely, whether it is regulated by AMPK and vice versa, whether v-ATPase activation can affect AMPK function. Accordingly, the present study was designed to evaluate the expression and functional role of four different v-ATPase subunits (V1A, catalytic; V1B2, regulatory; V1C, assembly; v0c, transmembrane proton extrusion) in hHSCs isolated from cirrhotic liver (in vivo activated HSCs) and in in vitro activated primary hHSCs. We assessed whether changing pHi by v-ATPase inhibition could affect hHSC activation and whether v-ATPase expression and activity can be modulated by specific AMPKa subunits. Finally, we evaluated whether the pharmacological activation of AMPK is able to affect v-ATPase activity. In order to provide translational information, the expression of v-ATPase was investigated in human liver tissue obtained from healthy subjects and subjects with cirrhosis and by employing the bile duct ligation (BDL) animal model of liver fibrosis.
Our results indicate that increased v-ATPase expression is a key feature of activated hHSCs as well
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as of liver tissue characterized by active fibrogenesis. v-ATPase inhibition is able to induce a net downregulation of the hHSC profibrogenic phenotype, whereas pharmacological activation of AMPK decreases v-ATPase expression and prevents extracellular acidification by hHSCs in an AMPKa1-dependent manner.
Materials and Methods
A complete description of materials and methods can be found in the Supporting Information.
CELL CULTURES
Cells were isolated from wedge sections of human liver obtained from patients undergoing liver resections at the Royal Free Hospital after giving informed consent (EC01.14-RF). Cell isolation was performed according to a published protocol, (14) with modifications for human liver. (15) 
TREATMENTS
Primary hHSCs were cultured in 20% serumenriched medium for 24 hours, followed by incubation in serum-free medium (SFM) for 24 hours before each experimental treatment to avoid interference with growth factors and amino acids enriched in fetal bovine serum. (16) (17) (18) Data obtained from cells cultured in complete medium (CM) are reported in figure legends. Specific treatment with the v-ATPase inhibitors bafilomycin A1 and KM91104; with the AMPK activators diflunisal, A769662, and ZLN024 hydrochloride; and with TGFb1 and PDGF-BB are described in the Supporting Information.
INTRACELLULAR ATP
hHSCs were seeded at a density of 10,000 cells/ well/100 lL in a 96-well plate in CM and serumstarved for 24 hours, followed by incubation with the v-ATPase inhibitors for 48 hours. Cell lysis was induced using the CellTiter-Glo Reagent (Promega), according to the manufacturer's specification. Luminescence was recorded, and the intracellular ATP concentration was calculated from an ATP standard curve and normalized to hHSC proliferation.
ANIMAL MODELS OF LIVER CIRRHOSIS
Male, Balb/c mice were obtained from the comparative biological unit at the Royal Free and University College Medical School (Royal Free Campus, London, UK). All animals were given free access to normal rodent chow (expanded SDSRM 1; Special Diet Services, Witham, UK) and water. BDL or a sham operation was performed as described. (19) Experiments were terminated after 14 days, and liver tissue was snapfrozen and stored at 2808C until further analysis.
STATISTICAL ANALYSIS
In vitro experiments were carried out with a minimum of three independent cell preparations and at least three experimental replicates. Results are expressed as mean values 6 SEM and compared using one-way analysis of variance followed by Dunnett's or Tukey's multiple comparison post hoc tests or compared using a Student t test, where appropriate (GraphPad Prism; GraphPad, La Jolla, CA). P 0.05 was considered significant.
Results

INCREASED EXPRESSION OF v-ATPase IN IN VIVO AND IN VITRO ACTIVATED hHSCs
v-ATPase protein expression was evaluated in hHSCs and compared between freshly isolated hHSCs obtained from cirrhotic liver, i.e., in vivo activated cells, and from freshly isolated hHSCs obtained from healthy liver. Expression of the v-ATPase catalytic V1A, the regulatory V1B2, and the transmembrane proton extrusion v0c subunits was up-regulated in hHSCs isolated from cirrhotic liver in comparison to hHSCs obtained from normal, healthy liver, whereas the assembly subunit V1C was scarcely detectable (Fig.  1A) . Furthermore, variations in v-ATPase protein expression during the process of in vitro hHSC activation were assessed from culture passage 1 to subsequent culture passage 4 and demonstrated a significant increase in protein expression for subunits V1A, V1C, and v0c with a tendency to increase for the V1B2 subunit (Fig. 1B) .
In the next set of experiments, cells were treated for 24 hours with PDGF-BB or TGFb1, and v-ATPase subunit V0c mRNA expression showed a tendency to 3 1142 increase upon TGFb1 stimulation, whereas at the protein level v-ATPase subunit v0c showed a tendency to be down-regulated by PDGF-BB (Supporting Fig.  S2 ), indicating possible posttranslational modifications upon treatment with specific stimuli. Next, the total protein and intracellular distributions were investigated as the activity of v-ATPases in vivo is tightly regulated by reversible association and dissociation of the V1 and V0 domains; thus, when functionally assembled vATPase is localized in intracellular compartments/ membranes and in the plasma membrane. (20) No significant changes were observed in total protein expression between cells cultured in serum-rich CM and SFM (Fig. 1C) . In contrast, subcellular protein fractionation analysis showed that hHSCs cultured in CM, containing growth factors and amino acids, expressed all v-ATPase subunits predominantly at the membrane level, whereas in serum-starved hHSCs the V1B2 subunit became more cytosolic (Fig. 1D ), suggesting an intracellular compartmentalization and dynamic translocation of v-ATPase subunits under different culture conditions.
To investigate the possible association between vATPase and AMPK in hHSCs, we first investigated the expression of different AMPKa subunits in hHSCs in serum-rich and serum-starved conditions. AMPKa1 mRNA expression was significantly upregulated in SFM conditions in comparison to hHSCs cultured in CM (Fig. 1E ), whereas no differences were observed at the protein level (Fig. 1F) , suggesting posttranslational modifications. AMPKa2 protein expression was barely detectable in hHSCs as assessed by quantitative RT-PCR (Fig. 1E ), western blot analysis (60 lg), and immunofluorescence (Fig. 1F) .
Overall, these results indicate that v-ATPase is highly expressed in in vivo activated hHSCs and that the expression increases during in vitro culture activation. Moreover, AMPKa1, in contrast to AMPKa2, is strongly expressed in hHSCs.
v-ATPase INHIBITION AFFECTS hHSC PROLIFERATION, METABOLIC ACTIVITY, AND PROFIBROGENIC PHENOTYPE
To better define how v-ATPase activity affects hHSC activation, cells were treated for 48 hours with the v-ATPase inhibitor bafilomycin, which inhibits specifically the v-ATPase proton pump (v-ATPase transmembrane proton extrusion v0c subunit), (21) and KM91104, which specifically targets the interaction between v-ATPase subunit a3 and subunit B2. (22) Upon treatment, cells exhibited a marked reduction in metabolic activity ( Fig. 2A) , a dose-dependent decrease in cell proliferation (Fig. 2B) , and a dosedependent increase in intracellular ATP levels (Fig.  2C) . Of note, bafilomycin-induced v-ATPase inhibition coincided with a significant down-regulation of the mRNA expression of HSC activation markers such as alpha-smooth muscle actin (a-SMA) (Fig.  2D ) and procollagen I (Fig. 2E) , while KM91104 was ineffective. These experiments clearly demonstrated that both inhibitors, due to their different modes of action, interfere differently with the regulation of different v-ATPase subunits.
v-ATPase REGULATES pHi OF hHSCs
Next, v-ATPase activity and inhibition were assessed to clarify the differences in the effects of the two v-ATPase inhibitors. KM91104-treated hHSCs showed reduced expression of all v-ATPase subunits (Fig. 3A-D) , while bafilomycin-treated hHSCs showed a significant down-regulation only of subunits V1C and v0c (Fig. 3C,D) . Next, the effect of both vATPase inhibitors was further assessed on pH homeostasis by employing a neutral red uptake assay. Serumstarved hHSCs displayed a higher neutral red uptake in comparison to cells cultured in CM, reflecting a more acidic pH inside the intracellular compartments, i.e., lysosomes and endosomes (Fig. 3E) . In contrast, bafilomycin treatment (10 nM) in the serum-free condition reversed this effect as demonstrated by a decreased uptake of neutral red when compared to control cells. Similar results, but less prominent, were obtained with KM91104 treatment (Fig. 3E) . Furthermore, changes in cytosolic pH were quantified by employing a fluoro-
Treatment with 10 nM bafilomycin or 10 nM KM91104 was followed by a significant decrease in cytosolic pH (Fig. 3F) . Because inhibition by bafilomycin had a marked effect on hHSC profibrogenic phenotype (Fig. 2) , pHi was measured following an acidic load with NH 4 Cl. The pHi of both bafilomycin-treated (1 nM) and control cells increased rapidly over 8 minutes, i.e., steep slope (Fig. 3G) . In contrast, a less steep steady slope (<45.8%) was observed in 10 nM bafilomycin-treated hHSCs, with a higher increase in baseline pHi after 1 minute of acidic load, in comparison to vehicle-treated cells (Fig. 3G) . Next, v-ATPase activity as a proton 5 1144 pump at the plasma membrane was assessed by quantifying the extracellular pH in all cell culture media, which proved to be more acidified in v-ATPase inhibitortreated cells in comparison to vehicle-treated hHSCs (Supporting Table S1 ). Overall, these data suggest an important role for v-ATPase in pH homeostasis but also highlight the function of non-v-ATPase-related pumps which become active to compensate for the reduction/ loss of v-ATPase activity following treatment with specific inhibitor. Next, the phosphorylation of AMPK at Thr172 was analyzed to further investigate whether inhibition of v-ATPase activity affects AMPK activity in hHSCs. Bafilomycin treatment for 48 hours resulted in a marked increase in AMPK phosphorylation (Fig. 3H) .
Taken together, these findings suggest that v-ATPase inhibition by different pharmacological inhibitors correlates with changes in pHi and extracellular pH homeostasis in hHSCs. Furthermore, v-ATPase inhibition by bafilomycin, but not KM91104, leads to activation/ phosphorylation of AMPK and inhibition of hHSCs' profibrogenic profile.
PHARMACOLOGICAL ACTIVATION OF AMPK DOWN-REGULATES v-ATPase EXPRESSION IN hHSCs
To investigate the role of the AMPK-v-ATPasepH axis in hHSCs, cells were treated with the 
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AMPK allosteric, direct activators A769662 (23) and ZLN024, (24) both of which inhibit the dephosphorylation of phosphorylated AMPK, and diflunisal, a salicylic acid derivative with analgesic and antiinflammatory effects, which has been shown to act as a strong cAMP response element-binding protein binding protein (CBP)/p300 inhibitor. (25, 26) First, the effect of all activators was tested on hHSC metabolic activity and proliferation (Supporting Fig. S1 ). Cells treated with diflunisal (100 lM) showed a significant decrease in metabolic activity and proliferation, without morphological changes indicative of cell death, whereas 1 mM was clearly cytotoxic (Supporting Fig. S1A-C) . Treatment with A769662 showed no significant effect on metabolic activity and proliferation at the dose of 10 lM, whereas higher doses (100-200 lM) were cytotoxic. Treatment with ZLN024 had no effect on hHSC metabolic activity and proliferation (Supporting Fig. S1C-E) . Next, AMPK activation was assessed by an employing enzyme-linked immunosorbent assay to quantify the phosphorylation of AMPK Thr172 in hHSCs treated with all AMPK activators under investigation. Treatment with 100 lM of diflunisal or 10 lM of A769662 and ZLN024 at all the concentrations employed resulted in increased AMPK phosphorylation of Thr172 AMPK (Fig. 4A) . Of all the AMPK activators tested, only diflunisal treatment demonstrated a reduction in hHSC metabolic activity and proliferation (Supporting Fig. S1A ), which correlated with increased AMPK phosphorylation. Diflunisal further induced AMPK's downstream target acetyl-coenzyme A carboxylase by phosphorylating Ser79 (Fig. 4B) . Of note, diflunisal treatment induced a down-regulation of a-SMA (Fig. 4C ) and procollagen I (Fig. 4D) , as was shown for hHSCs treated with the v-ATPase inhibitor bafilomycin (Fig. 2D,E) . Importantly, activation of AMPK by diflunisal and A769662, but not ZLN024, was associated with a decreased protein expression of all vATPase subunits (Fig. 4E) and coincided with changes in v-ATPase activity as shown by 51% and 38% reductions in extracellular H 1 concentration, respectively (Supporting Table S2 ). These data demonstrate that the compounds tested have different modes of AMPK activation in hHSCs. In addition, we show that both diflunisal and A769662 reduced v-ATPase expression, while ZLN024 had no effect. These data demonstrate that pharmacological activation of AMPK in hHSCs is correlated with vATPase protein expression and activity.
v-ATPase EXPRESSION IS DIFFERENTIALLY REGULATED BY AMPKa1 AND AMPKa2, AND AMPKa1 REGULATES v-ATPase IN hHSCs
The data so far suggest that inhibition of v-ATPase activity leads to activation of AMPK and that vice versa activation of AMPK reduces v-ATPase activity. Therefore, we further defined the role of different AMPK subunits on each v-ATPase expression/activation in well-characterized genetically modified mouse embryo fibroblasts (MEFs) deficient for specific subunits, i.e., AMPKa1, AMPKa2, and AMPKa1a2. First, the mRNA expression of all v-ATPase subunits was assessed in the different AMPKa-deficient fibroblasts. The expression of all v-ATPase subunits was significantly higher in AMPKa2-null MEFs in comparison to the other AMPKa-deficient fibroblasts and wild-type (WT) MEFs (Fig. 5A ). AMPKa1a2-null MEFs showed increased expression of all subunits, with V1C and v0c showing significantly higher expression in comparison to WT MEFs. AMPKa1-null MEFs showed a significant increase in the regulatory subunit V1B2 and a strong decrease in the transmembrane proton extrusion v0c subunit compared to WT MEFs. These data indicate that a deficiency in a specific AMPK subunit coincides with variations in vATPase subunit gene expression.
To further define whether the previously observed decrease in v-ATPase expression in diflunisal-treated and A769662-treated cells was AMPK-dependent (Fig. 4) , WT and AMPKa1a2-null MEFs were treated with diflunisal and A769662 for 24 hours. Diflunisal-treated WT MEFs showed a significant decrease in protein expression in all four v-ATPase subunits (Fig. 5B ) similar to diflunisal-treated hHSCs (Fig. 4E) , whereas in diflunisal-treated AMPKa1a2-null MEFs, this down-regulation in V1A and V1B2 protein expression was abrogated, indicating an AMPK-dependent effect (Fig. 5B) . On the other hand, a small but significant decrease in V1C and v0c expression was still observed in AMPKa1a2-null treated cells, indicating AMPK-independent effects (Fig. 5B) . In contrast to diflunisal, A769662 treatment had a significant effect on V1C and v0c in WT cells and v0c expression in AMPKa1a2-null MEFs but no effect on V1A and V1B2 subunits in both cell types under investigation.
Next, small interfering RNA (siRNA) against AMPKa1 was employed to investigate whether the expression of v-ATPase was AMPKa1-dependent in 8 1147
hHSCs (Fig. 5C ). siRNA-depleted AMPKa1 hHSCs were treated with diflunisal and A769662, and vATPase protein expression was assessed. Interestingly, the previously observed diflunisal-induced and A769662-induced down-regulation of v-ATPase V1A, V1B2, and V1C expression (Fig. 4E ) was completely prevented in AMPKa1-silenced hHSCs (small interfering control versus small interfering AMPKa1) (Fig. 5D) , while the down-regulation of v0c expression was partially abrogated (Fig. 5D) . Furthermore, silencing of AMPKa1 expression in hHSCs revealed that diflunisal and A769662 pharmacological 
v-ATPase EXPRESSION IS UP-REGULATED IN VIVO AND IN HUMAN LIVER CIRRHOSIS
In vivo activation of HSCs is the result of the interaction with the surrounding cellular and molecular microenvironment undergoing sustained injury. Thus, we analyzed v-ATPase expression in a BDL mouse model of liver fibrosis and in liver tissue obtained from healthy subjects and patients with cirrhosis. A significant increase in mRNA levels of V1B2 and v0c was observed in BDL-induced animals, whereas no significant changes were observed for V1A and V1C subunits, in comparison to sham-control mice (Fig. 6A) . This was further confirmed at the protein level (Fig.  6B) . Next, immunohistochemistry showed a colocalization of a-SMA-positive hHSCs with v-ATPase in the perisinusoidal space of Disse and that all four vATPase subunits exhibited increased expression and cellular distribution in punctate/granular structures in human cirrhotic liver tissue (markedly enhanced in parenchymal cells) in comparison to healthy liver (Fig.  6C) . Taken together, these results indicated that vATPase is increased in fibrotic mouse tissue and in human cirrhotic livers, corroborating its implication in the initiation and progression of the fibrogenic process occurring in chronic liver diseases.
Discussion
HSCs are the main cellular effectors of liver fibrogenesis. (1, 2) To date, no antifibrotic therapies for chronic liver disease have been introduced in clinical practice. (27) (28) (29) v-ATPases are large multisubunit complexes (V 1 V 0 ) and are ATP-dependent proton (H 1 ) pumps which regulate pH homeostasis by pumping H 1 against their electrochemical gradient. Thus, vATPase acidifies intracellular compartments by pumping H 1 into lysosomes and by pumping out H 1 across the plasma membrane and into the extracellular space. (30) We hypothesized that the higher baseline pHi found in activated HSCs may originate not only from the activity of the Na 1 /H 1 exchanger (3, 4) but also from v-ATPase expression and activity. We found that all four v-ATPase subunits under investigation were highly expressed in fibrotic tissue of mice and cirrhotic human livers, as well as in hHSCs activated both in vitro and in vivo. Moreover, intracellular vATPase was localized in intracellular compartments and on the plasma membrane depending on different culture conditions. These observations led to the hypothesis that v-ATPase could play an important role in regulating H 1 fluxes throughout the cell upon changes in the microenvironment like those occurring in conditions of chronic liver tissue damage and progressive fibrogenesis. (31) The pioneer studies of Di Sario and colleagues demonstrated the importance of the Na 1 /H 1 exchanger in pHi regulation in HSCs. (4) With the present work we have demonstrated a key role for v-ATPase and its association with AMPK in regulating pHi in primary hHSCs (Fig. 7) . Bafilomycin-induced inhibition of vATPase led to AMPK phosphorylation, which correlated with a significant reduction in the hHSC profibrogenic profile. This observation is in agreement with data demonstrating that bafilomycin-treated murine HSCs did not acquire a myofibroblast-like phenotype as a consequence of a decreased autophagic flux. (32) In our study, down-regulation of procollagen I and a-SMA was observed after treatment with bafilomycin but not with KM91104. This could be explained by the fact that bafilomycin and KM91104 inhibit v-ATPase with different modalities. Bafilomycin acts by inhibiting proton flow through the v-ATPase pump, (21) although after 48 hours of treatment an acute acid load is still able to induce an increment in pH. This suggests that other pumps, such as the Na 1 / H 1 exchanger, are still active and exert a compensatory effect for the lack of active v-ATPase. (3, 33, 34) In contrast, KM91104 is a weaker inhibitor than bafilomycin because it specifically targets the interaction between v-ATPase subunits a3 and B2, (22) without interfering with the pump activity.
To investigate the role of the AMPK-v-ATPasepH axis in hHSCs, we demonstrated that primary hHSCs express predominantly AMPKa1, whereas AMPKa2 is scarcely detectable (Fig. 1E,F) and genetically modified AMPKa1/a2 MEFs (23) showed a clear association between different v-ATPase subunits and specific AMPKa subunits. Furthermore, cells were treated with the AMPK allosteric, direct activators A769662 (23) and ZLN024, (24) both known to inhibit dephosphorylation of phosphorylated AMPK, and diflunisal, a salicylic acid derivative with analgesic and anti-inflammatory effects, which has been shown to be a strong CBP/p300 inhibitor (25, 26) and very recently demonstrated to be key in activation of hHSCs. (35) 11 1150 12 1151
We demonstrate that both diflunisal and A769662 reduce v-ATPase expression, while ZLN024 had no effect. In addition, diflunisal down-regulates hHSC activation markers in a manner similar to what has been observed in hHSCs treated with the v-ATPase inhibitor bafilomycin. These results are in line with a recent study demonstrating different working mechanisms through which salicylihalamide A and bafilomycin inhibit v-ATPase (25) as some effects of salicylatebased drugs, particularly on cellular metabolism, are mediated by AMPK. (26) Importantly, our study demonstrates that diflunisal acts as an AMPK activator in hHSCs. Furthermore, diflunisal-induced down-regulation in the expression of specific v-ATPase subunits was completely prevented in MEFs deficient of AMPKa1a2, further corroborating the correlation between v-ATPase and AMPK. These findings were further explored in hHSCs silenced for AMPKa1 and revealed that siRNA against AMPKa1 abrogates the down-regulation in v-ATPase and that diflunisal and A769662 exert their effect specifically on v-ATPase. Moreover, the importance of v-ATPase was further shown in an in vivo model of fibrosis and in human liver tissues, demonstrating a colocalization of a-SMA-positive cells with v-ATPase subunits and an increased expression of v-ATPase in diseased liver.
In conclusion, this study demonstrates that pharmacological inhibition of v-ATPase through AMPKa1 leads to inhibition of the profibrogenic hHSC phenotype. Accordingly, our results provide a solid platform for the design of drugs acting on the AMPK-vATPase-pH axis as potential strategies for the treatment of liver fibrosis.
